Skip to main content

CORRECTION article

Front. Med., 12 December 2022
Sec. Dermatology
Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.1106530

Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

This article is a correction to:

  1. Case Report: Challenges in the Diagnosis of a Case of Mal de Meleda and a Therapeutic Attempt of Ixekizumab and Adalimumab

    1. Read original article
\nYuwei Dai,,,,&#x;Yuwei Dai1,2,3,4,5†Xiaodong Zheng,,,&#x;Xiaodong Zheng1,2,3,4†Qi Zhang,,,,Qi Zhang1,2,3,4,5Xia Hu,,,,Xia Hu1,2,3,4,5Peiguang Wang,,, Peiguang Wang1,2,3,4*Sen Yang,,,, Sen Yang1,2,3,4,5*
  • 1Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China
  • 2Institute of Dermatology, Anhui Medical University, Hefei, China
  • 3Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, Hefei, China
  • 4Provincial Laboratory of Inflammatory and Immune Mediated Diseases, Hefei, China
  • 5Ferry Outpatient Department, The Ferry Skin Research Institute, Hefei, China

A corrigendum on
Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

by Dai, Y., Zheng, X., Zhang, Q., Hu, X., Wang, P., and Yang, S. (2022). Front. Med. 9:821301. doi: 10.3389/fmed.2022.821301

In the published article, there was an error in the dosage of adalimumab. A correction has been made to Report, 1. This sentence previously stated:

“One month later, Adalimumab with dose of 300 mg was given subcutaneously.”

The corrected sentence appears below:

“One month later, Adalimumab with dose of 40 mg was given subcutaneously.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Mal de Meleda, MDM, Exomiser, HPO terms, Ixekizumab, Adalimumab

Citation: Dai Y, Zheng X, Zhang Q, Hu X, Wang P and Yang S (2022) Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab. Front. Med. 9:1106530. doi: 10.3389/fmed.2022.1106530

Received: 23 November 2022; Accepted: 30 November 2022;
Published: 12 December 2022.

Edited and reviewed by: Andreas Recke, University of Lübeck, Germany

Copyright © 2022 Dai, Zheng, Zhang, Hu, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Peiguang Wang, ✉ wpg2370@163.com; Sen Yang, ✉ yang2004sen@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.